poisar

Stocks · News reference

This Principal Financial Group Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

Avi Kapoor

Top Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See what analysts think of these stocks.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

APGEFTHJDNUVLPFGSPCXVVX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Apogee Therapeutics, Inc. (APGE)

    Filed: 2026-09-03 AccNo: 0001140361-26-035537 Size: 348 KB Item 1.02: Termination of a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits

    APGE
  2. Delveinsight

    Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

    DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.

    PFEGMABKPTIIOVABNTX
  3. Zacks.Com

    Principal Financial (PFG) Moves 6.5% Higher: Will This Strength Last?

    Principal Financial rallied 6.5% to close at $118.51 on higher trading volume. The company is expected to report quarterly earnings of $2.53 per share (+20.5% YoY) and revenues of $4.29 billion (+10.2% YoY). However, consensus EPS estimates have been revised marginally lower over the past 30 days, and the stock carries a Zacks Rank #3 (Hold) rating, suggesting the recent strength may not be sustainable.

    PFGORI
  5. Na

    PFG Enhances Retirement Plans Through Partner Expansion

    Principal Financial Group is expanding its Featured Partner Program to integrate private-market investment strategies into defined-contribution retirement plans through collective investment trusts. The expansion partners with major asset managers including Blackstone, Apollo, KKR, and others to offer plan sponsors diversified investment options, potentially driving asset growth and fee opportunities for PFG's Retirement and Income Solutions business.

    PFGHMNMTGAIZAIZN